Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial - European Urology
ASCO GU 2020: Overall Survival in Men with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Receiving Bicalutamide Followed by Enzalutamide or Abiraterone
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer - Annals of Oncology
Olaparib for Metastatic Castration-Resistant Prostate Cancer | NEJM
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate | Prostate Cancer and Prostatic Diseases
Overall survival. mCRPC metastatic castration-resistant protate cancer.... | Download Scientific Diagram
Advances in Treating mCRPC: Focus on Immunotherapy
Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel? - Clinical Genitourinary Cancer
Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors | SpringerLink
ASCO GU 2019: The CHEIRON Study - A Multicentric Phase II Randomized Trial of Docetaxel Plus Enzalutamide versus Docetaxel as First-Line Chemotherapy for Patients with mCRPC
View Image
Genomic correlates of clinical outcome in advanced prostate cancer | PNAS
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
Overall survival and second primary malignancies in men with metastatic prostate cancer
KaplaneMeier estimates of OS from mCRPC diagnosis according to the type... | Download Scientific Diagram
PLOS ONE: Overall survival and second primary malignancies in men with metastatic prostate cancer
The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study - ScienceDirect
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | Semantic Scholar
Visceral Metastases and Prostate Cancer Treatment: 'Die Hard,' 'Tough Neighborhoods,' or 'Evil Humors'?
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial - Annals of Oncology
Optimal sequencing of commonly used medications for treatment of metastatic castration-resistant prostate cancer - Mayo Clinic
Model Simplifies mCRPC Patient Prognoses - Renal and Urology News
TERRAIN Trial Efficacy and Safety | XTANDI® (enzalutamide) Safety Info
Clinical Parameters Predict Overall Survival in mCRPC | PracticeUpdate
Advances in Treating mCRPC: Focus on Immunotherapy
Association between CTC AR-V7 and overall survival in mCRPC. A total... | Download Scientific Diagram
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors - European Urology
